Adverse events following percutaneous and surgical coronary revascularisation: Analysis of non-MACE outcomes in the Stent or Surgery (SoS) Trial

Autor: Ulrich Sigwart, Jean Booth, Raphael A. Perry, Rod Stables, Elved B. Roberts
Rok vydání: 2016
Předmět:
Male
medicine.medical_specialty
Time Factors
medicine.medical_treatment
Coronary Artery Disease
030204 cardiovascular system & hematology
law.invention
03 medical and health sciences
Coronary artery bypass surgery
Percutaneous Coronary Intervention
Postoperative Complications
0302 clinical medicine
Randomized controlled trial
law
Cause of Death
Outcome Assessment
Health Care
medicine
Humans
Cumulative incidence
Hospital Mortality
cardiovascular diseases
030212 general & internal medicine
Coronary Artery Bypass
Adverse effect
Retrospective Studies
business.industry
Incidence
Percutaneous coronary intervention
Stent
Length of Stay
Middle Aged
Prognosis
Surgery
Europe
Survival Rate
surgical procedures
operative
Conventional PCI
Female
Stents
Cardiology and Cardiovascular Medicine
business
Mace
Follow-Up Studies
Zdroj: International Journal of Cardiology. 202:7-12
ISSN: 0167-5273
Popis: To analyse adverse events requiring or prolonging hospitalisation in the Stent or Surgery (SoS) trial.Many adverse events following coronary revascularisation are non-major adverse cardiovascular events (non-MACE). Trials comparing percutaneous coronary intervention (PCI) and coronary artery bypass surgery (CABG) have reported rates of mortality and MACE only.Comparisons between PCI and CABG groups in the SOS trial were by intention to treat. For patients with non-fatal/non-MACE, number of events per 100 patient years follow-up and duration of hospital stay were assessed. Competing risk analysis was used to illustrate temporal pattern of adverse outcomes.During 2 y median follow up, 1 one or more adverse event occurred in 47.3% (231) of the PCI group and 53% (265) of the CABG group (p=0.086). Non-fatal/non-MACE occurred in 11.9% of the PCI group and 38.6% of the CABG group (p0.001). Non-fatal/non-MACE per 100 patient years follow-up was 17.49 (PCI) and 35.04 (CABG), rate ratio 2.0, 95% CI 1.7 to 2.4, p0.001. Cumulative non-fatal/non-MACE associated hospital stays were 1387 and 3287 days in PCI and CABG groups respectively. Median duration of hospitalisation per non-fatal/non-MACE was 5 days (interquartile range 2 to 11.75 days) in the PCI group and 6 days (interquartile range 2 to 12 days) in the CABG group, p=0.245.CABG had lower cumulative incidence of fatal or MACE outcomes, higher cumulative incidence of non-fatal/non-MACE outcomes, and longer cumulative hospitalisation periods compared to the PCI group.
Databáze: OpenAIRE
Externí odkaz: